ROCKVILLE, Md.–(BUSINESS WIRE)–Aug. 4, 2021– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its Board of Directors has appointed Harout Semerjian as chief executive officer (CEO), effective August 6, 2021, to succeed retiring Founding CEO Rachel King. Mr. Semerjian, a seasoned executive with strong oncology commercialization experience, will lead the company as it advances its registrational trials on its lead clinical candidate, uproleselan, in acute myeloid leukemia (AML), accelerates planning for potential commercialization, and continues to build out the company’s pipeline.
{iframe}https://ir.glycomimetics.com/news-releases/news-release-details/glycomimetics-names-harout-semerjian-new-chief-executive-officer{/iframe}